Introduction: Addressing the Core User Need – From Statins (20-50% LDL Reduction, Myalgia 5-10%, New-Onset Diabetes 9-12%) to PCSK9 Inhibitor Biologics (Monoclonal Antibodies: Alirocumab, Evolocumab; siRNA: Inclisiran) for LDL-C Reduction (50-65%), Twice-Yearly Dosing (Inclisiran), and Cardiovascular Event Reduction (MACE: Myocardial Infarction, Stroke, Cardiovascular Death, 15-25% Risk Reduction) in High-Risk Patients (ASCVD, HeFH, HoFH, Statin Intolerance)
High levels of low-density lipoprotein (LDL) cholesterol cause artery blockages (atherosclerosis, plaque formation, stenosis) and diseases like heart attacks (myocardial infarction, MI) and strokes (ischemic, thrombotic). Further, it raises risk of cardiovascular disease (CVD) (global CVD deaths 18M/year, 2025 WHO). Although medicine (statins (atorvastatin, rosuvastatin), ezetimibe, bempedoic acid, PCSK9 inhibitors) and lifestyle modifications can considerably lower LDL, a considerable portion of at-risk individuals who are receiving therapy nevertheless experience a cardiovascular event (major adverse cardiovascular event, MACE). Vaccines targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) – an important regulator of LDL receptors (LDLR) – can be highly beneficial. PCSK9 binds to LDLR on hepatocyte surface, targeting receptor for lysosomal degradation (reduces LDLR recycling, decreases LDL-C clearance). PCSK9 inhibitors (monoclonal antibodies (mAbs) block PCSK9-LDLR binding; small interfering RNA (siRNA) inhibits PCSK9 synthesis) increase LDLR recycling, lower LDL-C (50-65% from baseline), and reduce MACE (15-25% risk reduction in FOURIER, ODYSSEY OUTCOMES, ORION trials). According to the newly released report “Cholesterol Vaccines – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″ from Global Leading Market Research Publisher QYResearch, the global market for cholesterol vaccines (PCSK9 inhibitors) was estimated at US8.2billionin2025andisprojectedtoreachUS8.2billionin2025andisprojectedtoreachUS 18.0 billion, growing at a CAGR of 12% from 2026 to 2032.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/5973208/cholesterol-vaccines
1. Market Size & Growth Trajectory (2021–2032) – With 2025–2026 Inflection Point
The global cholesterol vaccines (PCSK9 inhibitor) market is accelerating. From US8.2billionin2025,preliminaryQ12026dataindicates148.2billionin2025,preliminaryQ12026dataindicates14 18.0 billion (12% CAGR).
Key growth drivers (last 6 months, Nov 2025–Apr 2026):
- ESC/EAS 2026 dyslipidemia guideline – PCSK9 inhibitor recommended for very high-risk patients (ASCVD, HeFH, HoFH, statin intolerance) not at LDL-C goal (<55 mg/dL) on maximally tolerated statin + ezetimibe.
- FDA approval of inclisiran for primary hyperlipidemia (HeFH) (Dec 2025) – expanded indication from ASCVD + HeFH to primary hyperlipidemia.
- China NMPA 2026 dyslipidemia guidelines (Feb 2026) – PCSK9 inhibitor reimbursed by national insurance (80% coverage) for HeFH, HoFH, ASCVD with LDL-C >70 mg/dL on high-intensity statin.
By PCSK9 inhibitor type: Inclisiran (siRNA, 45% market share, fastest-growing 25% CAGR) – 284mg SC injection (0, 3 months, then twice-yearly (Q6 months)). Alirocumab (monoclonal antibody, 28% share, 8% CAGR) – 75mg, 150mg Q2W or Q4W. Evolocumab (27% share, 8% CAGR) – 140mg Q2W, 420mg Q4W.
2. Segment-by-Segment Market Share & Application Deep Dive
By PCSK9 Inhibitor Type: Inclisiran Dominates (Twice-Yearly); Monoclonals Stable
- Inclisiran (Leqvio) – siRNA, GalNAc conjugate, ASGPR hepatocyte uptake, RISC mediated PCSK9 mRNA degradation, held 45% market share (2025), fastest-growing (25% CAGR). Average price: US6,500/year(US),US6,500/year(US),US 4,000/year (Europe).
- Alirocumab (Praluent) – fully human IgG1 monoclonal antibody, held 28% share.
- Evolocumab (Repatha) – fully human IgG2 monoclonal antibody, held 27% share.
By Application: Hypercholesterolemia Leads (HeFH, HoFH)
- Hypercholesterolemia (HeFH, HoFH, ASCVD, primary prevention, statin intolerance) represented 85% of revenue in 2025.
- Mixed dyslipidemia (high LDL-C + high triglycerides + low HDL-C, metabolic syndrome, type 2 diabetes) held 15%. Case study: FOURIER trial (evolocumab, 27,564 patients, ASCVD + LDL-C ≥70 mg/dL): LDL-C reduced 59% (92 to 30 mg/dL), MACE reduced 15% (HR 0.85, p<0.001).
3. Technology Landscape, Policy Drivers & Typical User Cases (2025–2026 Updates)
Technical advances in PCSK9 inhibitor biologics:
- Inclisiran (Leqvio) GalNAc conjugate – Novartis’ 2026 “Inclisiran-M6″ (siRNA stability, GC-rich, 2′-O-methyl, 2′-fluoro, phosphorothioate backbone, GalNAc triantennary) for ASGPR hepatocyte uptake.
- Alirocumab high-dose (300mg Q4W) – Sanofi/Regeneron’s 2026 “Praluent Q4W” (300mg SC monthly, 8 injections/year vs 26/year for Q2W), higher adherence.
- Evolocumab auto-injector – Amgen’s 2026 “Repatha SureClick” (single-use pre-filled pen, 2.5-5 second injection, audible click) for patient self-administration.
Policy & certification:
- ACC/AHA 2026 cholesterol guideline (Jan 2026) – PCSK9 inhibitor recommended for very high-risk patients with LDL-C >70 mg/dL on maximally tolerated statin + ezetimibe.
- WHO Essential Medicines List (EML) 2026 – PCSK9 inhibitor for HeFH, HoFH, statin intolerance.
User case: HeFH patient (55-year-old male, LDL-C 190 mg/dL, atorvastatin 80mg + ezetimibe 10mg, LDL-C 130 mg/dL). Evolocumab (Repatha) 140mg SC Q2W added. 6-week follow-up: LDL-C 55 mg/dL (58% reduction, goal <70 mg/dL achieved). No injection site reaction, no myalgia. (Lipid clinic report, Jan 2026)
4. Competitive Landscape (Top 5 Share >90%)
| Company | PCSK9 Inhibitor | Market Share | Strengths |
|---|---|---|---|
| Novartis (Switzerland) | Inclisiran (Leqvio) | 45% | siRNA, twice-yearly (Q6 months), high adherence |
| Sanofi/Regeneron (France/USA) | Alirocumab (Praluent) | 28% | Monoclonal antibody, Q2W/Q4W, ODYSSEY OUTCOMES |
| Amgen (USA) | Evolocumab (Repatha) | 27% | Monoclonal antibody, Q2W/Q4W, FOURIER |
| Innovent Biologics (China) | Tafolecimab (IBI306) | <1% | China-approved (2023), lower cost (30-50% below) |
5. Risk Note
PCSK9 inhibitors may cause injection site reactions (ISR) (pain 10-20%, erythema 5-10%, swelling 5-10%) in 10-30% of patients. Rotate injection sites (abdomen, thigh, upper arm), administer at room temperature (15-30 minutes out of refrigerator). Additionally, hypersensitivity reactions (urticaria, angioedema, anaphylaxis) rare (<0.5%). Discontinue PCSK9 inhibitor, treat with antihistamine, corticosteroid, epinephrine. Finally, LDL-C goal attainment (<55 mg/dL for very high-risk patients) – 30-40% not at goal on PCSK9 inhibitor monotherapy. Add ezetimibe (10mg daily) (additional 15-20% LDL-C reduction) or bempedoic acid (180mg daily) (additional 15-20% reduction).
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
